Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S16, June 2016

Results of a First-in-Man Study of Mesenchymal Stem Cell Therapy for Bronchiolitis Obliterans Syndrome

      Introduction: Bone marrow derived mesenchymal stem cells (MSC) represent an attractive cellular therapeutic target given their immunosuppressive and tolerogenic properties and relative immune privilege. Preclinical studies and human trials in graft versus host disease suggest potential efficacy in bronchiolitis obliterans syndrome (BOS). The purpose of this dual centre, phase 1 study ( NCT01175655) was to explore the feasibility and safety of delivery of allogeneic MSC in patients with BOS complicating lung transplantation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect